MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

UM-164

CAS No. : 903564-48-7

產品活性：UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits p38α and p38β.

研究領域：Protein Tyrosine Kinase/RTK  |  MAPK/ERK Pathway  |  Autophagy

作用靶點：Src  |  p38 MAPK  |  Autophagy

In Vitro: In biochemical assays, UM-164 is a highly potent inhibitor of c-Src with a binding constant comparable with Dasatinib (UM-164 K_d=2.7 nM, Dasatinib K_d=0.7 nM). To confirm that UM-164 is capable of inhibiting the activation of c-Src in vitro, the effect of UM-164 is examined on the c-Src autophosphorylation in two TNBC cell lines (MDA-MB 231 and SUM 149). Inhibition of c-Src autophosphorylation is detected in a concentration- and a time-dependent manner. At 120 minutes, complete abrogation of c-Src autophosphorylation is observed at 50 nM, demonstrating that UM-164 is a potent c-Src inhibitor in vitro. Flow cytometry experiments demonstrate that UM-164 treatment of MDA-MB 231 and SUM 149 increased the proportion of G₀-G₁ cells by 25% and 28%, respectively, and concurrently decreased the fraction of S cells by 16% and 19%, respectively.

In Vivo: A xenograft study is performed using NCr/nude mice implanted with MDA-MB 231 and SUM 149 cell lines. Once the tumors become palpable, the mice are randomized into control and treatment groups. Mice are injected intraperitoneally with either drug (10 and 20 mg/kg in both xenograft studies; a 15 mg/kg dose is added to the SUM 149 xenograft studies) or vehicle every other day (n=5 for each group). At the selected doses of UM-164, there is no significant weight loss or gross abnormalities observed in the treated animals, even after 52 days of treatment. However, tumor growth is significantly inhibited in both the 10 mg/kg and 20 mg/kg dose groups compared with the vehicle-treated group (P<0.026 and P<0.004, respectively).

相關產品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Antidepressant Compound Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Tirbanibulin dihydrochloride  |  HIV-IN-6  |  Bisabolangelone  |  4-Hydroxylonchocarpin  |  Bafetinib  |  Multi-kinase-IN-2  |  PP2  |  TLR4/NF-κB/MAPK-IN-1  |  PP58  |  Broussonin E  |  L-threo-Sphingosine  |  SB 242235  |  ENMD-2076 Tartrate  |  Hydrangenol  |  Lck-IN-1  |  EGF-R (661-681) T669 Peptide  |  TA-01  |  Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH  |  AMG-548 hydrochloride  |  Ponatinib hydrochloride  |  JX401  |  Ganoderterpene A  |  VX-702  |  TL02-59 dihydrochloride  |  Esculin  |  R1487 Hydrochloride  |  Emprumapimod  |  BMS-751324  |  A-770041  |  p38α inhibitor 3

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業技術服務；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業團隊跟蹤新的制藥及生命科學研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構建立了長期的合作。